Actual evaluation and data analysis of the therapeutic effect of venetoclax/venetoclax (venetoclax)

Veneclar has shown significant efficacy in patients with chronic lymphocytic leukemia (CLL). Clinical data shows that the progression-free survival (PFS) and overall survival rate of patients treated with venetoclax combined with obinutuzumab are significantly better than traditional chemotherapy regimens. Some studies have shown that after 6 years of treatment, the proportion of patients without disease progression can reach more than 50%, and the risk of recurrence is significantly reduced. These data demonstrate that venetoclax has reliable long-term efficacy in patients who have failed prior chemotherapy or are at high risk.

In patients with acute myeloid leukemia (AML), venetoclax is usually given in combination with azacitidine or low-dose cytarabine. Studies have shown that the complete response rate of this type of combination regimen ranges from 20% to 40%, and the median overall survival can be extended to about 14 months, which is significantly better than single drug treatment. For patients who are elderly or unable to tolerate standard chemotherapy, this combination provides a new and effective treatment option and improves the response rate that is difficult to achieve with previous treatments.

In real-world clinical use, the efficacy of venetoclax is consistent with clinical trial results. A multicenter retrospective study showed that progression-free survival and response rates in patients with CLL treated with venetoclax in daily medical settings were consistent with trial data. At the same time, for patients with AML and high-risk myelodysplastic syndrome (MDS), venetoclax combined with low-dose chemotherapy has shown good tolerability and controllable side effects, providing strong evidence for clinical promotion.

Common side effects of venetoclax include neutropenia, anemia, nausea, diarrhea, and fatigue. Serious side effects such as tumor lysis syndrome require risk assessment in advance and preventive measures, such as gradually increasing the dose and monitoring blood indicators. Patients should regularly review blood routine during use, and suspend or adjust the dose when serious adverse reactions occur. Under the guidance of a doctor, reasonable management of side effects can ensure the efficacy of Venetoclax while improving medication safety, allowing patients to obtain the best therapeutic effect.

Reference materials:https://www.drugs.com/